SEC Form 4Coverage since May 26, 2026
$NAMS insider trading
Over the last 12 months, NewAmsterdam Pharma insiders reported no purchases and 3 sales totaling $6.7M across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $6.7M 3 events
- Events · 12m
- 3 Form 4 filings, grouped
- Insiders · 12m
- 1 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $NAMS · 12Mvia TradingView
Top insiders · 12m
Kooij Louise FrederikaChief Accounting Officer3× · $6.7M
All insider trades
3 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 20, 2026 | Kooij Louise FrederikaChief Accounting Officer · O | ▼ Sale | 105,000 | $30.34 | $3.2M | -81.2% | plan · 3 tranches |
| Jun 22, 2026 | Kooij Louise FrederikaChief Accounting Officer · O | ▼ Sale | 40,000 | $30.2 | $1.2M | -62.2% | plan · 2 tranches |
| May 26, 2026 | Kooij Louise FrederikaChief Accounting Officer · O | ▼ Sale | 65,000 | $35.69 | $2.3M | -72.7% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $NAMS feed.